Global Anti-malarial Medicines Market 2018-2022 | Strong Funding to Eradicate Malaria Will Spur Growth | Technavio
LONDON--(BUSINESS WIRE)--Oct 9, 2018--The global anti-malarial medicines market 2018-2022 is expected to post a CAGR of close to 5% during the forecast period, according to the latest market research report by .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181009005923/en/
Technavio predicts the global anti-malarial medicines market is expected to post a CAGR of close to 5% by 2022. (Graphic: Business Wire)
A key factor driving the growth of the market is a strong funding to eradicate malaria. The funding for is increasing day by day as it is on the eradication list of the WHO. Various government and non-government organizations, such as MMV, Bill & Melinda Gates Foundation, and The World Bank, are conducting various awareness camps, which are supported by strong funding. The WHO Global Malaria Program (GMP) is coordinating the WHO’s global effort to control and eliminate malaria.
This market research report on the also provides an analysis of the most important trends expected to impact the market outlook during the forecast period. Technavio classifies an emerging trend as a major factor that has the potential to significantly impact the market and contribute to its growth or decline.
In this report, Technavio highlights the enhancement of the POC and biomarkers for malaria as one of the key emerging trends in the global anti-malarial medicines market:
Global anti-malarial medicines market: Enhancement of the POC and biomarkers for malaria
Diagnostics and biomarkers are being introduced to the world. Innovative and better diagnostics are necessary for the potential control of . Biomarkers are useful for disease management as well as for formulating strategies before the onset of the disease. Many studies are conducted to formulate such strategies. As of now, the most proficient technique for diagnosing malaria is the traditional blood smear analyzer.
“The Alere Malaria Ag P.f test introduced by Abbott is a rapid test and is ten times more sensitive than the current malaria RDTs for detection for the P.falciparum HRP-II antigen. This enables significantly better identification of individuals with very low parasitemia, with and without the evident symptoms of malaria infection,” says a senior analyst at Technavio for research on infectious and rare diseases.
Global anti-malarial medicines market: Segmentation analysis
This market research report segments the global anti-malarial medicines market by product (artemisinin compounds, quinolines, and related compounds, and other compounds) and geographical regions (APAC, EMEA, and the Americas).
The EMEA led the market in 2017 with a market share of more than 48%, followed by APAC and the Americas respectively. The region is expected to continue to dominate the market during the forecast period.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Five Forces Analysis
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20181009005923/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY INFECTIOUS DISEASES PHARMACEUTICAL
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 10/09/2018 12:19 PM/DISC: 10/09/2018 12:19 PM